

# Avacta Group PLC

20:21 03 Jun 2019

## Avacta plans for exciting cancer immunotherapy

Avacta Group PLC (LON:AVCT) has said it will go to clinic "well ahead of original plans" with a drug candidate that combines its binding protein technology with chemotherapy.

The group's tumour microenvironment activated drug conjugates (TMAC) are a ground-breaking new form of cancer immunotherapy.

Co-invented with Tufts University Medical School of the US, TMAC brings together Avacta's Affimers with chemotherapies in a single drug using a linker that is designed to only release the chemo in the tumour.

The plan is to gain permission for phase I trial in early 2020 to test the potential new treatment in people with certain types of solid tumours.

### Major milestone

The company called the first-in-man study "a major de-risking milestone for the programme".

"What is so attractive about Avacta's Affimer TMAC programme is that it offers a way to combine chemotherapy with immune checkpoint inhibitors without exposing the whole body to the same level of the chemo-toxin," said chief executive Alastair Smith.

"Whilst immunotherapies offer great promise for cancer patients, it is well established that only a relatively small sub-group of patients see durable responses to single immune checkpoint therapies. Avacta is directly addressing this urgent clinical need with its novel Affimer TMAC and bispecific programmes," he added.

### Targeted approach

In order to test the TMAC linker in humans for the first time, a chemo treatment called doxorubicin will be modified with the Avacta linker, rendering it inactive and harmless until the linker is split in the tumour, releasing an active cancer-killing agent.

Doxorubicin has well-documented safety issues limiting its dosing, and also putting a cap on the number patients that can be treated with it.

The shares rose 8% on the news, to change hands for 32.12p. Broker finnCap's target price is 125p.


Analyst Mark Brewer told investors: "Not only is this testing of the TMAC linker well ahead of original plans, but it potentially creates additional sources of non-dilutive funding from licensing the linker to create effective chemotherapeutic pro-drugs that are currently limited by dose-limiting systemic toxicities.

"Proving the enzyme-sensitive linker works in humans also increases the prospect of licensing the Affimer TMAC platform before clinical data are generated from its first Affimer TMAC."

**Price:** 20

**Market Cap:** £35.19 m

### 1 Year Share Price Graph



November 2018 May 2019 November 20

### Share Information

**Code:** AVCT

**Listing:** AIM

**52 week High Low**  
49.8 15

**Sector:** Pharma & Biotech

**Website:** [www.avacta.com](http://www.avacta.com)

### Company Synopsis:

At Avacta we have developed Affimer technology, an engineered alternative to antibodies. Based on a small protein, Affimer technology can be quickly developed to bind with high specificity and affinity to a wide range of targets. Affimer proteins can be developed as therapeutic molecules and can be used in a wide range of other life sciences applications in research and diagnostics.

[action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

Avacta's TMAC linker has been shown to increase the maximum tolerated dose by a factor of six in a pre-clinical study in mice.

**---adds share price and broker comment---**

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Avacta Group PLC named herein, including the promotion by the Company of Avacta Group PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).